Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term intermittent maintenance treatment with tacrolimus ointment in pediatric atopic dermatitis
2015-001040-11Phase 3
- Sponsor
- Astellas Pharma
- Start
- Apr 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in atopic dermatitis (AD) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Time of first relapse.
02
Drugs
tacrolimus
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2015-001040-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001040-11.